In the last week, the United States market has been flat, yet it has experienced a 13% increase over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these positive earnings expectations but also demonstrate innovation and adaptability in an evolving economic landscape.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 26.38% | 39.09% | ★★★★★★ |
Mereo BioPharma Group | 53.63% | 66.57% | ★★★★★★ |
Ardelyx | 20.78% | 59.46% | ★★★★★★ |
Travere Therapeutics | 26.41% | 64.47% | ★★★★★★ |
TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
AVITA Medical | 27.28% | 60.66% | ★★★★★★ |
Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
Alnylam Pharmaceuticals | 23.64% | 61.12% | ★★★★★★ |
Ascendis Pharma | 35.15% | 60.20% | ★★★★★★ |
Lumentum Holdings | 21.59% | 110.32% | ★★★★★★ |
Click here to see the full list of 228 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics across the United States, Europe, Canada, and Japan with a market cap of $12.64 billion.
Operations: Incyte generates revenue primarily from its biotechnology segment, amounting to $4.41 billion. The company is involved in the discovery, development, and commercialization of therapeutics across multiple regions including the United States, Europe, Canada, and Japan.
Incyte's recent FDA approval of Zyny for squamous cell carcinoma and the settlement with Novartis highlight its strategic advances and potential cost reductions. Despite a challenging year with a 97.1% drop in earnings growth, projections are optimistic with an expected 20.94% annual earnings growth over the next three years. The company's commitment to R&D is evident from its significant investment, aligning with its focus on innovative cancer treatments and immune therapies that could redefine treatment paradigms in their respective fields.
Learn about Incyte's historical performance.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: monday.com Ltd., along with its subsidiaries, develops software applications globally, including in the United States, Europe, the Middle East, Africa, and the United Kingdom; it has a market cap of approximately $15.44 billion.
Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $1.04 billion. Its operations span across multiple regions, offering software solutions internationally.
With a robust trajectory in both revenue and earnings, monday.com has demonstrated significant growth potential. In Q1 2025, the company's sales surged to $282.25 million from $216.91 million year-over-year, with net income escalating to $27.43 million from $7.08 million, reflecting a sharp increase in profitability and operational efficiency. This performance is underpinned by an aggressive R&D strategy that continually fuels innovation—evident from its recent forecast suggesting a 24% to 26% revenue growth for FY2025, aligning with its strategic market expansions and leadership enhancements such as the appointment of Casey George as CRO. These developments collectively underscore monday.com's adeptness at navigating the competitive tech landscape while maintaining strong growth momentum in software solutions.
Gain insights into monday.com's past trends and performance with our Past report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: TKO Group Holdings, Inc. is a sports and entertainment company with a market capitalization of approximately $31.58 billion.
Operations: TKO Group Holdings generates revenue primarily through its UFC and WWE segments, contributing approximately $1.45 billion and $1.47 billion respectively. The company operates in the sports and entertainment sector with a focus on these prominent brands.
TKO Group Holdings, Inc. has shown a notable uptick in its financial performance, with a recent revision in 2025's full-year revenue forecast to range between $3.005 billion and $3.075 billion, reflecting strong early-year results from its UFC and WWE segments. This adjustment represents an increase from earlier projections of $2.930 billion to $3.000 billion, underpinning the company's robust operational dynamics within the entertainment sector. Moreover, TKO's strategic partnerships and product launches, such as the new co-branded venture with Seagram’s Escapes Spiked and WWE, demonstrate innovative market engagement strategies that enhance brand visibility and consumer reach across diverse demographics. The company also maintains shareholder value through consistent dividend payouts, with a recent declaration set at $0.38 per share for Class A stockholders—a testament to its commitment to returning capital to investors amidst expanding market operations.
Gain insights into TKO Group Holdings' historical performance by reviewing our past performance report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:INCY NasdaqGS:MNDY and NYSE:TKO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.